Media coverage about Regeneron Pharmaceuticals (NASDAQ:REGN) has been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Regeneron Pharmaceuticals earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 82 out of 100, indicating that recent media coverage is very likely to have an effect on the stock’s share price in the near future.
Here are some of the news headlines that may have impacted Accern’s rankings:
- Regeneron Pharmaceuticals Inc (REGN) Stock Looks Good Despite the Backdrop (investorplace.com)
- Piper Jaffray Companies Increases Regeneron Pharmaceuticals, Inc. (REGN) Price Target to $557.00 (americanbankingnews.com)
- The Axa Has $31.44 Million Position in Regeneron Pharmaceuticals, Inc. (REGN) (campdesrecrues.com)
- Regeneron Pharmaceuticals’ $REGN “Hold” Rating Reiterated at Oppenheimer Holdings, Inc. https://t.co/ZYpXPvKQOC (4-traders.com)
- Regeneron Pharmaceuticals Sees Unusually Large Options Volume (REGN) (thewestcoastsportsblog.com)
Regeneron Pharmaceuticals (REGN) traded up 5.02% during trading on Tuesday, hitting $495.33. 2,134,815 shares of the stock were exchanged. The stock has a market cap of $52.29 billion, a price-to-earnings ratio of 59.96 and a beta of 1.53. The firm’s 50 day moving average price is $453.36 and its 200-day moving average price is $392.99. Regeneron Pharmaceuticals has a 1-year low of $325.35 and a 1-year high of $504.89.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported $2.92 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.42. Regeneron Pharmaceuticals had a return on equity of 22.99% and a net margin of 19.34%. The business had revenue of $1.32 billion for the quarter, compared to analysts’ expectations of $1.30 billion. During the same quarter in the prior year, the business earned $2.57 EPS. The firm’s revenue for the quarter was up 9.8% on a year-over-year basis. On average, analysts anticipate that Regeneron Pharmaceuticals will post $12.66 EPS for the current year.
Several equities analysts have recently weighed in on REGN shares. BTIG Research restated a “buy” rating and set a $460.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, March 20th. Leerink Swann set a $448.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, March 28th. Piper Jaffray Companies set a $446.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, March 8th. Vetr lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $408.86 price objective for the company. in a research report on Monday, April 24th. Finally, Zacks Investment Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $416.00 price objective for the company in a research report on Thursday, April 27th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and twelve have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $438.99.
In other news, major shareholder Sanofi acquired 136,050 shares of the stock in a transaction on Friday, June 2nd. The shares were purchased at an average price of $478.17 per share, for a total transaction of $65,055,028.50. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Neil Stahl sold 2,812 shares of the stock in a transaction on Friday, June 2nd. The stock was sold at an average price of $479.49, for a total value of $1,348,325.88. Following the transaction, the executive vice president now owns 28,477 shares in the company, valued at approximately $13,654,436.73. The disclosure for this sale can be found here. In the last 90 days, insiders sold 46,821 shares of company stock worth $21,753,312. 10.40% of the stock is owned by company insiders.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.